Mocetinostat

DB11830InvestigationalSmall molecule

Mocetinostat has been used in trials studying the treatment of Lymphoma, Urothelial Carcinoma, Relapsed and Refractory, Myelodysplastic Syndrome, and Metastatic Leiomyosarcoma, among others.

Mechanism: Mocetinostat is a novel isotypic-selective inhibitor of the enzyme histone deacetylase (HDAC). HDAC inhibitors act by turning on tumour suppressor genes that have been inappropriately turned off. Tumour suppressor genes are a natural defense against cancer. It is therefore hypothesized that specifically inhibiting those HDACs involved in cancer with Mocetinostat may restore normal cell function and reduce or inhibit tumour growth.
Curator reviewed
Formula / weight: C₂₃H₂₀N₆O · 396.454 g/mol (avg)
Code names: MGCD-0103

Resolves to

Compound

UNIIA6GWB8T96JCAS726169-73-9ChEMBLCHEMBL272980ChEBI94525PubChem9865515

Structure

InChIKeyHRNLUBSXIHFDHP-UHFFFAOYSA-NSMILESNC1=CC=CC=C1NC(=O)C1=CC=C(CNC2=NC=CC(=N2)C2=CC=CN=C2)C=C1

Targets

Q9BY41HDAC8Q13547HDAC1Q96DB2HDAC11O15379HDAC3Q92769HDAC2

What you can answer from here — as of September 12, 2026

5Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

424Drug interactionsStructured to mechanism, not free text

21Clinical trialsPhase, status and sponsor resolved per trial

25+ReferencesStructured and connected to the statements they support

Which drugs share a target with Mocetinostat, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account